Bind Therapeutics, Pfizer deal

Bind (formerly Bind Biosciences Inc.) and Pfizer partnered to develop and commercialize Accurins using undisclosed small molecules provided by the pharma for undisclosed diseases. Accurins are selective and programmable nanoparticle-encapsulated therapeutics that are designed to accumulate at the site of disease. Bind will use its Medicinal Nanoengineering technology to develop the Accurins. ...